Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Novelty Nobility, Inc.
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06805825CT.gov A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chromophobe Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| nn3201 (this asset) | Novelty Nobility, Inc. | P1 | CC · 43 |
| Cabozantinib | Bradley A. McGregor, MD | P2 | B |
| Pazopanib | Mayo Clinic | P2 | B |
| Nivolumab | Bradley A. McGregor, MD | P2 | CCC |
| Ipilimumab | Bradley A. McGregor, MD | P2 | CCC |
| Sorafenib | National Cancer Institute (NCI) | P1/2 | CCC |
| Cytokine Induced Memory-Like Natural Killer Cells | Dana-Farber Cancer Institute | Early P1 | C |
| Glucose, Anhydrous | University of Texas Southwestern Medical Center | N/A | D |
| Glutamine | University of Texas Southwestern Medical Center | N/A | D |
+3 more in the Chromophobe Renal Cell Carcinoma cohort
Other indications for nn3201
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastrointestinal Stromal Tumor | — | P1 | CC · 43 |
| Adenoid Cystic Carcinoma | — | P1 | CC · 43 |
| Small Cell Lung Carcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. nn3201 in Chromophobe Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nn3201-chromophobe-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →